VORVor Biopharma Inc.vs its industry peers
A metric-by-metric comparison of Vor Biopharma Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VORThis | $1.3B#2 | 0.1x#1 | — | — | — | -495.3%#3 | — | — | — | — | -29.8%#1 | — |
| CGEM | $1.3B#1 | — | 3.2x#1 | — | -100.0%#2 | -31.2%#2 | — | -53.8%#1 | — | — | — | — |
| MGTX | $1.2B#3 | 14.7x#2 | — | 15.1x#1 | 144.6%#1 | 22.7%#1 | -130.2%#1 | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice